ABT earnings release — EPS $1.31 vs $1.28 est · revenue $12.6B vs $12.5B est · gross margin 56.3% · operating margin 16.5%雅培 (ABT) 财报快讯 — EPS $1.31 vs $1.28 预期 · 营收 $12.6B vs $12.5B 预期 · 毛利率 56.3% · 经营利润率 16.5%
Abbott Laboratories (ABT) Q2 2026 Earnings Beat Estimates, Raises Full-Year EPS Guidance
Abbott Laboratories released its Q2 2026 financial results at 7:30 ET on July 16, 2026, reporting adjusted diluted EPS of $1.31 (beating consensus $1.28) and total revenue of $12.6B (beating consensus $12.5B), with official press release and SEC 8-K filing published the same day.
Actual vs Consensus Results
Adjusted diluted EPS came in 2.3% above consensus estimates, while total revenue exceeded forecasts by 0.5%, with both core metrics beating market expectations.
Earnings Quality Metrics
GAAP diluted EPS for the quarter was $0.53, with gross margin at 56.3%, operating margin at 16.5%, and EBITDA margin at 20.1%. Operating cash flow totaled $1.3B, capital expenditures were $399M, resulting in $916M in free cash flow. As of quarter end, the company held $6.8B in cash, $34.0B in total debt, and $27.2B in net debt. Compared to Q1 2026 (ended March 31, 2026), Q2 revenue grew 13% YoY, with comparable sales growth of 4.8%, while Q1 revenue saw a 2.6% YoY decline and operating income fell 18.2% YoY.
Guidance Updates
The company reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, and raised its full-year adjusted EPS guidance range to $5.45 to $5.60, up from the prior range of $5.38 to $5.58.
Independent Context
As of December 31, 2025, 3,310 institutional holders held 81.7% of ABT’s float, an increase of 68 holders from prior periods, with 321 new positions, 1,468 increased positions, and 1,347 reduced positions. On June 18, 2026, director John G. Stratton purchased 2,000 shares at $86.82 per share, a confirmed insider buy signal.
Follow-up Markers
Investors should wait for: 1) The official Q2 2026 10-Q filing to verify segment-level revenue and cash flow details; 2) The earnings call transcript for business segment operating updates; 3) Specific capital expenditure allocation details to assess free cash flow sustainability. This signal does not confirm long-term YoY revenue growth durability or provide granular order backlog data.
雅培实验室（ABT）2026年第二季度财报超预期并上调全年EPS指引
雅培实验室于2026年7月16日7:30正式发布2026年第二季度财报，调整后摊薄每股收益（EPS）为1.31美元，超出市场共识预期1.28美元，总营收126亿美元，超出共识预期125亿美元，官方新闻稿与SEC 8-K文件同日披露。
实际与共识对比
本季度调整后摊薄EPS实际值较共识预期高出2.3%，总营收超幅0.5%，两项核心财务指标均实现小幅超预期。
财报质量分析
本季度GAAP摊薄EPS为0.53美元，毛利率56.3%，营业利润率16.5%，EBITDA利润率20.1%。经营现金流达13亿美元，资本支出3.99亿美元，自由现金流9.16亿美元。截至季度末公司持有现金68亿美元，总债务340亿美元，净债务272亿美元。对比一季度（截至3月31日）数据，本季度营收同比增长13%，可比销售增长4.8%，而一季度营收同比下滑2.6%，营业利润同比下滑18.2%。
指引更新情况
公司重申2026年全年可比销售增长指引为6.5%至7.5%，将全年调整后EPS指引区间从此前的5.38-5.58美元上调至5.45-5.60美元。
独立背景参考
截至2025年底，共有3310家机构持有ABT 81.7%的流通股，较此前增加68家，其中321家新建仓、1468家加仓。2026年6月18日，董事John G Stratton以每股86.82美元的价格增持2000股公司股票，为明确的内部人买入信号。
后续关注事项
投资者需等待：1）2026年二季度正式10-Q文件以验证细分业务营收与现金流明细；2）财报电话会议纪要以获取各业务板块运营细节；3）资本支出具体投向以评估自由现金流可持续性。本信号未证明长期营收增长的可持续性，也未涵盖细分业务的订单变化情况。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。